Effect of Nursing Intervention on Treatment Burden and Self-management Among Adolescents With Thalassemia

November 19, 2026 updated by: Abbas Obaid Mijbas, University of Baghdad

Effect of an Orem's Self-care Theory -Based Nursing Intervention on Treatment Burden and Self-management Among Adolescents With Thalassemia

This study aims to evaluate the effect of a nursing intervention based on Orem's self-care theory on treatment burden and self-management among adolescents diagnosed with thalassemia. Adolescents with thalassemia face significant physical and psychosocial challenges that affect their daily routines and treatment adherence. The intervention consists of educational and supportive sessions designed to enhance self-care agency and reduce treatment burden. Participants will be evaluated before and after the implementation of the nursing program to measure changes in treatment burden and self-management behaviors.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. adolescents aged 12-18 years.
  2. diagnosed with β-thalassemia major/transfusion-dependent β-thalassemia by a physician.
  3. Receiving regular blood transfusion therapy according to their treatment plan.
  4. Receiving regular iron chelation therapy.
  5. Able to communication and understanding sufficiently to complete in intervention.
  6. Willing to participate in the study with written informed assent from the adolescent and informed consent from the parent/ legal guardian.

Exclusion Criteria:

  1. adolescents with sever medical complication.
  2. adolescents with sever cognitive, intellectual, or developmental impairment that prevent understanding or participation in study.
  3. participants who have undergone or currently undergoing hematopoietic stem cell transplantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
Experimental: Intervention group

A structured educational and supportive nursing program based on Orem's self-care theory, designed to enhance self-care agency, improve disease self-management, and reduce treatment burden among adolescents with thalassemia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-management
Time Frame: 8 weeks

Mean Score of Self-Management Measured by the Self-management and transition to adulthood with Rx (STARx).

Self-management behaviors will be assessed using a validated Self-Management Questionnaire. The total score ranges from [0] to [90], where higher scores indicate better self-management practices.

Baseline (pre-intervention) and 8 weeks post-intervention

8 weeks
Treatment Burden
Time Frame: 8 weeks

Treatment burden will be evaluated using the validated The Medication-Related Burden Quality of Life (MRB-QoL) . The total score ranges from [31] to [155], where higher scores indicate a greater perceived burden of treatment Baseline (pre-intervention) and 8 weeks post-intervention

8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Asmahan Q Mohammed, University of Baghdad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 13, 2026

Primary Completion (Estimated)

February 15, 2027

Study Completion (Estimated)

April 10, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 19, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 19, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Mijbas-2026-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.